AR058752A1 - Composiciones para bebes para prevenir la obesidad - Google Patents

Composiciones para bebes para prevenir la obesidad

Info

Publication number
AR058752A1
AR058752A1 ARP060105799A ARP060105799A AR058752A1 AR 058752 A1 AR058752 A1 AR 058752A1 AR P060105799 A ARP060105799 A AR P060105799A AR P060105799 A ARP060105799 A AR P060105799A AR 058752 A1 AR058752 A1 AR 058752A1
Authority
AR
Argentina
Prior art keywords
fatty acids
weight
pufa
ala
total fatty
Prior art date
Application number
ARP060105799A
Other languages
English (en)
Inventor
Johannes Wilhelmus Chri Sijben
Renate Maria Louise Zwijssen
Gunther Boehm
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36072152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NL2006/050274 external-priority patent/WO2008054192A1/en
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of AR058752A1 publication Critical patent/AR058752A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pediatric Medicine (AREA)

Abstract

Un método para prevenir la obesidad en la vida adulta administrando determinadas composiciones nutricionales a ninos de entre 0 y 36 meses. Reivindicacion 1: El uso de una composicion que comprende un componente de lípidos, proteínas e hidratos de carbono digeribles, donde el componente lipídico comprende: (i) ácido linoleico (LA) y ácido alfa-linolénico (ALA), con una relacion en peso LA/ALA de entre 2 y 7; (ii) menos de 15% en peso de LA, sobre la base de los ácidos grasos totales; y (iii) al menos 1% en peso de ALA, sobre la base de los ácidos grasos totales, y donde la composicion comprende además al menos un componente seleccionado del grupo que consiste en: (a) 3-50% en peso de ácidos grasos de cadena media (MCFA), sobre la base de los ácidos rasos totales y (b) ácidos grasos de cadena larga con multiples insaturaciones n-6 (LC-PUFA) y n-3 LC-PUFA, con una relacion en peso inferior a 1,5, entre 0,02 y 0,8% en peso de n-6 LC-PUFA, sobre la base de los ácidos grasos totales, y al menos 0,2% en peso de n-3 LC-PUFA, sobre la base de los ácidos grasos totales, para la fabricacion de una composicion nutricional que será administrada a un bebé no obeso con una edad inferior a 36 meses, para la prevencion de la obesidad.
ARP060105799A 2005-12-23 2006-12-26 Composiciones para bebes para prevenir la obesidad AR058752A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20050077972 EP1800675B1 (en) 2005-12-23 2005-12-23 Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
PCT/NL2006/050274 WO2008054192A1 (en) 2006-11-02 2006-11-02 Use of nutritional compositions for preventing disorders

Publications (1)

Publication Number Publication Date
AR058752A1 true AR058752A1 (es) 2008-02-20

Family

ID=36072152

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP060105800A AR058753A1 (es) 2005-12-23 2006-12-26 Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
ARP060105798A AR058751A1 (es) 2005-12-23 2006-12-26 Composiciones de alimento para bebes para prevenir la obesidad
ARP060105799A AR058752A1 (es) 2005-12-23 2006-12-26 Composiciones para bebes para prevenir la obesidad

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP060105800A AR058753A1 (es) 2005-12-23 2006-12-26 Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
ARP060105798A AR058751A1 (es) 2005-12-23 2006-12-26 Composiciones de alimento para bebes para prevenir la obesidad

Country Status (12)

Country Link
US (8) US8119142B2 (es)
EP (13) EP1800675B1 (es)
CN (8) CN101389227B (es)
AR (3) AR058753A1 (es)
AT (1) ATE509624T1 (es)
BR (3) BRPI0620244A2 (es)
DK (1) DK1800675T3 (es)
ES (4) ES2366034T3 (es)
MY (2) MY172306A (es)
PL (4) PL1800675T4 (es)
PT (1) PT1800675E (es)
WO (4) WO2007073178A2 (es)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951842B1 (en) * 1999-01-20 2002-12-04 N.V. Nutricia Infant formula
WO2007063143A1 (es) * 2005-11-30 2007-06-07 Katry Inversiones, S.L. Mezcla de lipidos y su utilización para preparar un producto destinado a la adminitracion enteral u oral
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
US20080146579A1 (en) * 2006-12-15 2008-06-19 N.V. Nutricia Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore
US8835396B2 (en) 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
ES2352154T3 (es) * 2007-01-23 2011-02-16 Bioenergy Inc. Uso de d-ribosa para tratar arritmias cardiacas.
JP2008189637A (ja) * 2007-02-08 2008-08-21 Snow Brand Milk Prod Co Ltd 自己免疫疾患予防剤
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009002166A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Improving memory in subjects with mini-mental state examination of 24-26
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
PL2190304T3 (pl) * 2007-09-17 2012-04-30 Nutricia Nv Preparat odżywczy o wysokiej wartości energetycznej
CN101820754A (zh) 2007-10-04 2010-09-01 雀巢产品技术援助有限公司 用于增强认知功能的组合物与方法
KR101290514B1 (ko) * 2007-10-25 2013-07-26 뉴트리 가부시키가이샤 혈중의 당, 말론디알데히드 수식 ｌｄｌ, 호모시스테인 및/또는 ｃ 반응성 단백질을 저감시키기 위한 조성물
CN101896119A (zh) * 2007-11-02 2010-11-24 麻省理工学院 尿苷饮食添加顺应性方法及其用途
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
WO2009066685A1 (ja) * 2007-11-19 2009-05-28 Snow Brand Milk Products Co., Ltd. 感覚改善剤
PL2222311T3 (pl) 2007-12-20 2013-08-30 Nutricia Nv Ciekły produkt zawierający nukleotydy/nukleozydy
RU2478309C2 (ru) * 2007-12-21 2013-04-10 Н.В. Нютрисиа Применение сфингомиелина и неперевариваемых углеводов для нормализации микробиоты кишечника
CA2994586C (en) 2008-01-04 2020-07-21 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
WO2009127073A1 (de) * 2008-04-18 2009-10-22 Gen Sod2 Foundation Auf ein individuum abgestimmte kosmetikzubereitung und verfahren zu deren herstellung
US20090286750A1 (en) * 2008-05-16 2009-11-19 Kasubick Robert V Use of ribose in lessening the clinical symptoms of aberrant firing of neurons
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
ES2382150T5 (es) * 2008-06-16 2022-10-03 Nutricia Nv Fórmula de leche de bebé con gradiente de grasa
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
MY160275A (en) 2008-09-02 2017-02-28 Nutricia Nv Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids
NZ571856A (en) * 2008-10-09 2011-02-25 Fonterra Corporate Res And Dev Ltd Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
BRPI0915247A2 (pt) * 2008-11-14 2016-02-16 Bomi P Framroze método para reduzir o complexo de oxldl-beta-2-glicoproteína circulante e mieloperoxidase circulante no soro humano, e, processo para a fabricação de uma composição de óleo dietética"
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
WO2010068086A1 (en) 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
MX2011008448A (es) 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
WO2010104374A1 (en) * 2009-03-09 2010-09-16 N.V. Nutricia Nutritional composition inducing a postprandial endocrine response
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
MX338680B (es) * 2009-05-11 2016-04-27 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) y padecimientos inmunes.
WO2010134800A1 (en) * 2009-05-19 2010-11-25 N.V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
WO2010137944A1 (en) 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
WO2011021926A1 (en) 2009-08-21 2011-02-24 N.V. Nutricia Regulating the amino acid pool used for the acute-phase protein synthesis
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
ES2569922T3 (es) * 2009-11-25 2016-05-13 Nestec S.A. Composiciones nutritivas, que incluyen un componente de alto contenido en proteínas y nucleótidos exógenos
WO2011071365A1 (en) * 2009-12-07 2011-06-16 N.V. Nutricia Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
WO2011115476A1 (en) * 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
WO2011121151A1 (es) * 2010-03-31 2011-10-06 Vegenat, S.A. Suplemento alimenticio funcional especialmente destinado para la nutrición, prevención y mejora en casos de alteraciones neurológicas, neurodegenerativas o trastornos cognitivos
EP2554057A4 (en) * 2010-03-31 2013-12-18 Vegenat S A ENERAL OR ORAL FOOD PRODUCT SPECIALLY FOR NUTRITION, PREVENTION AND MITIGATION OF NEUROLOGICAL OR NEURODEGENERATIVE ALTERATIONS OR COGNITIVE DISORDERS
WO2011139621A1 (en) * 2010-04-26 2011-11-10 Nestec S.A. Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition
WO2012030208A1 (en) * 2010-09-03 2012-03-08 N.V. Nutricia Method and preparation for the treatment or prevention of anxiety or neurogenesis
WO2012049227A2 (en) * 2010-10-12 2012-04-19 Vifor Sa Novel omega-3 and omega-6 fatty acid compositions and uses thereof
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012091542A1 (en) * 2010-12-28 2012-07-05 N.V. Nutricia Combination of components for the prevention and treatment of frailty
ES2875458T3 (es) * 2010-12-29 2021-11-10 Abbott Lab Producto nutricional para uso en la reducción de la incidencia de enterocolitis necrosante en un lactante, niño pequeño o niño
US8952000B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
WO2012112527A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
JP2014506891A (ja) * 2011-02-16 2014-03-20 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
EP2675445A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
WO2012112520A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
US8715648B2 (en) * 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
CA2827555A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
BR112013023770B1 (pt) * 2011-03-18 2020-12-15 Société des Produits Nestlé S.A. Composição útil para aliviar distúrbios relacionados à idade em um animal, e seu uso
WO2012173467A1 (en) * 2011-06-16 2012-12-20 N.V. Nutricia Metabolic imprinting effects of specifically designed lipid component
EP2734993A4 (en) * 2011-07-22 2014-10-15 Nestec Sa PROCESS FOR REDUCING ADIPOSITAS IN CHILDREN AND FOR CALCULATING ADIPOSITAS RISK IN CHILDREN
WO2013036103A1 (en) * 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with large lipid globules
WO2013036102A1 (en) * 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with cholesterol
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
TWI472300B (zh) 2011-12-27 2015-02-11 Abbott Lab 包含核苷酸及／或類胡蘿蔔素之低卡路里嬰兒配方於降低後續生命中不利健康效應之用途
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
BR112014020177A8 (pt) * 2012-03-02 2021-10-19 Nutricia Nv Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada
AU2013234830A1 (en) * 2012-03-16 2014-11-06 David Sprague Hemp-based infant formula and methods of making same
SE536599C3 (sv) * 2012-04-10 2017-01-10 Hero Ag Näringssammansättning med lågt kalori- och lågt proteininnehåll
SG11201408769QA (en) 2012-06-29 2015-01-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
EP2708146A1 (en) * 2012-09-17 2014-03-19 Abbott Laboratories, Inc. Nutritional composition for pregnant women with a beneficial glucose and insulin profile
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140199265A1 (en) * 2013-01-11 2014-07-17 Mead Johnson Nutrition Company Nutritional compositions containing a neurologic component and uses thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US10455854B2 (en) 2013-03-11 2019-10-29 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US9661874B2 (en) * 2013-03-11 2017-05-30 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US20140255537A1 (en) * 2013-03-11 2014-09-11 Mead Johnson Nutrition Company Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
US9980506B2 (en) * 2013-03-11 2018-05-29 Mead Johnson Nutrition Co. Nutritional compositions containing structured fat globules and uses thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US10335412B2 (en) * 2013-04-10 2019-07-02 Energenesis Biomedical Co., Ltd Method for activating AMPK and the use of adenine
WO2014171813A1 (en) * 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
US20140328970A1 (en) * 2013-05-03 2014-11-06 Mead Johnson Nutrition Company Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
CN105324037B (zh) * 2013-07-03 2018-02-23 荷兰联合利华有限公司 马铃薯来源的风味增强组合物及其制造方法
RU2532283C1 (ru) * 2013-07-12 2014-11-10 Наталья Николаевна Пыхтина Способ лечения задержки развития мелкой моторики у детей младшего возраста
US10709770B2 (en) 2013-07-31 2020-07-14 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US9609888B2 (en) 2013-07-31 2017-04-04 Mead Johnson Nutrition Company Nutritional compositions containing synergistic combination and uses thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
ES2693519T3 (es) 2013-11-01 2018-12-12 N.V. Nutricia Composición lipídica para mejorar la composición corporal durante el crecimiento de recuperación
ES2780690T3 (es) 2013-11-29 2020-08-26 Société des Produits Nestlé SA Composiciones nutricionales adaptadas a la edad con un contenido variable de proteínas
FR3015860B1 (fr) * 2013-12-30 2019-08-16 Pronokal Health Group, Sociedad Limitada Composition alimentaire de regime pour diminuer l'inflammation de bas grade a court et long terme comprenant de l'acide docosahexaenoique
CN104721174B (zh) * 2014-01-15 2016-08-24 南通大学 多异戊烯甲萘醌类化合物的新用途
WO2015115885A1 (en) 2014-01-31 2015-08-06 N.V. Nutricia Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
GB201405033D0 (en) 2014-03-20 2014-05-07 Isis Innovation Combination therapy
WO2015160233A1 (en) * 2014-04-14 2015-10-22 N.V. Nutricia Method for assessing and treating or preventing impaired plasma polar lipid levels
EP3131537A1 (en) 2014-04-14 2017-02-22 N.V. Nutricia Method for assessing and treating or preventing impaired plasma polar lipid levels
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016083362A1 (en) * 2014-11-25 2016-06-02 Fonden For Helene Elsass Centeret Composition for improving cognitive functions
US20160302451A1 (en) 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
US10582714B2 (en) 2015-07-10 2020-03-10 Mead Johnson Nutrition Company Nutritional compositions and methods for promoting cognitive development
EP3190099B1 (de) 2015-09-14 2020-10-28 Helmholtz-Zentrum Potsdam - Deutsches GeoForschungsZentrum GFZ Stiftung des Öffentlichen Rechts des Lands Brandenburg Neue fettsäure und ihre verwendung
WO2017064304A1 (en) 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
WO2017069613A1 (en) * 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
JP6423811B2 (ja) * 2016-02-29 2018-11-14 ファナック株式会社 加工情報に応じて加工条件を変更可能な数値制御装置
WO2017155387A1 (en) 2016-03-08 2017-09-14 N.V. Nutricia Method for supporting memory function and/or cognitive function
WO2017155386A1 (en) * 2016-03-08 2017-09-14 N.V. Nutricia Method for treating brain atrophy
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US20190151273A1 (en) 2016-04-04 2019-05-23 N.V. Nutricia Method for reducing or preventing global developmental delay in children
EP3445353A1 (en) * 2016-04-18 2019-02-27 N.V. Nutricia Linoleic acid and alpha-li nolenic acid for use for reducing early-life stress induced cognitive decline/reduction in neurogenesis
WO2018038599A1 (en) * 2016-08-23 2018-03-01 N.V. Nutricia Product and method for increasing uridine concentration in blood plasma
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
CN108148801A (zh) * 2016-12-06 2018-06-12 深圳先进技术研究院 多不饱和脂肪酸体外扩增髓系来源的抑制性细胞的方法
AU2017373837B2 (en) 2016-12-09 2022-07-14 N.V. Nutricia Nutritional composition for improving cell membranes
US10500206B2 (en) 2017-03-13 2019-12-10 Energenesis Biomedical Co., Ltd. Method for enhancing wound healing by administrating adenine
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
WO2019045036A1 (ja) 2017-09-01 2019-03-07 大鵬薬品工業株式会社 エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
CN109395084A (zh) * 2018-11-14 2019-03-01 威海市千谷生物科技有限公司 一种溶脂线和溶脂液及利用其的埋线减肥方法
CN109527094A (zh) * 2018-12-27 2019-03-29 安徽康博特保健食品有限公司 孕妇营养包特殊膳食蛋白粉及其制备方法
CN114144191A (zh) * 2019-05-14 2022-03-04 哈达斯特医疗研究服务和开发有限公司 用于治疗炎性肠病的源自于奶的细胞外囊泡
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
WO2021019580A1 (en) * 2019-07-26 2021-02-04 Prosol S.P.A. Composition comprising 5'-ribonucleotides for use in the treatment of alzheimer's disease
US20220280465A1 (en) * 2019-08-08 2022-09-08 Swinburne University Of Technology Uses of long-chain polyunsaturated fatty acids
EP4021208A4 (en) * 2019-10-29 2022-10-19 AAK AB (publ) NUTRITIONAL COMPOSITION COMPRISING PHOSPHOLIPIDS FROM MILK AND EGG
CN110840873A (zh) * 2019-11-28 2020-02-28 广东海洋大学 二十二碳五烯酸在制备预防和治疗精神分裂症药物中的应用
IT202000009700A1 (it) * 2020-05-04 2021-11-04 Parthenogen Sagl Combinazione di micronutrienti per stimolare la produzione endogena di sulfide di idrogeno (h2s)
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
EP4094591A1 (en) * 2021-05-28 2022-11-30 Fonterra Co-Operative Group Limited Food supplement
AU2022345465A1 (en) * 2021-09-17 2024-03-21 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
CN114965764A (zh) * 2022-05-18 2022-08-30 陕西安宁云生生物技术有限公司 便秘的诊断和治疗
CN115227706B (zh) * 2022-06-08 2023-12-29 陈玉松 5’-单磷酸核苷酸组合物在制备消脂减肥功能食品和药物中的应用
CN115006345B (zh) * 2022-06-28 2023-11-28 上海交通大学医学院附属瑞金医院 一种口服零价钼纳米点的制备方法与应用
WO2024003385A1 (en) * 2022-07-01 2024-01-04 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES507187A0 (es) 1981-11-16 1983-01-01 Union Ind Y Agro Ganader S A U Procedimiento de obtencion de una leche humanizada adiciona-da de nucleotidos con destino a la alimentacion infantil.
JPS60126220A (ja) 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
JPS6163624A (ja) * 1984-09-05 1986-04-01 Nisshin Oil Mills Ltd:The エイコサペンタエン酸含量の高い糖脂質の製造法
DE3603000A1 (de) * 1986-01-31 1987-08-06 Milupa Ag Neue polyensaeure-reiche fettmischung und deren verwendung bei der herstellung von saeuglingsnahrungen
AU612149B2 (en) * 1987-05-01 1991-07-04 Otsuka Pharmaceutical Co., Ltd. Nutritive emulsion preparation
ES2007350A6 (es) 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
AU769645B2 (en) 1987-05-29 2004-01-29 Abbott Laboratories Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation
ZA885473B (en) * 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
DE3734147C2 (de) 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
US5272138A (en) * 1988-02-12 1993-12-21 The Biomembrane Institute Naturally occurring gangliosides containing de-N-acetyl-sialic acid and their applications as modifiers of cell physiology
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
EP0367724B1 (en) * 1988-10-31 1993-02-10 Sandoz Nutrition Ltd. Improvements in or relating to organic compounds
ES2033193B1 (es) 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
IT1244770B (it) 1991-03-12 1994-08-08 Cem Spa Dispositivo per l'ordinamento di moduli stampati su striscia in continuo
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
WO1994027628A1 (en) * 1993-05-28 1994-12-08 Abbott Laboratories Enteral nutritional product
ATE409483T1 (de) 1994-01-10 2008-10-15 Abbott Lab Enterale zusammensetzung mit ribo-nucleotiden
US5602109A (en) 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
MY112798A (en) * 1994-02-04 2001-09-29 Karlshamns Lipidteknik Ab Oil-in-water emulsions
GB9403935D0 (en) * 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
DE19510765A1 (de) 1995-03-24 1996-09-26 Alexander Buehlbaecker Verfahren zur Herstellung von Frühgeborenen-, Säuglings- und Diätnahrung
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
CN1058845C (zh) * 1996-01-31 2000-11-29 高世虎 强化营养豆奶粉
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
AR022986A1 (es) 1996-08-12 2002-09-04 Gist Brocades Bv Produccion y uso de composiciones que comprenden concentraciones altas de actividad de vitamina b12
WO1998006277A1 (en) 1996-08-13 1998-02-19 Bristol-Myers Squibb Company Nutritional formulas supplemented with nucleotides, and processes thereof
US6391362B1 (en) 1996-08-27 2002-05-21 Ronald C. Gorewit Bulk preparation of milk fat globule membranes
JP4034370B2 (ja) * 1996-09-27 2008-01-16 雪印乳業株式会社 脳機能改善剤及び栄養組成物
US6194009B1 (en) * 1996-11-22 2001-02-27 Princeton Nutrition, Llc Refrigeration-shelf-stable ultra-pasteurized or pasteurized infant formula
CA2223198A1 (en) * 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
CN1660065A (zh) * 1997-03-27 2005-08-31 布里斯托尔-迈尔斯斯奎布公司 二十二碳六烯酸和花生四烯酸促进不足月婴儿生长的用途
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
FR2776208B1 (fr) 1998-03-20 2000-06-16 Agronomique Inst Nat Rech Produits, en particulier laitiers, comprenant des fractions selectionnees de globules gras, obtention et applications
US6194379B1 (en) * 1998-05-01 2001-02-27 Abbott Laboratories Elemental enteral formula
CN1239644A (zh) 1998-06-19 1999-12-29 张士林 一种天然营养品
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
WO2000006174A1 (en) 1998-07-31 2000-02-10 Massachusetts Institute Of Technology Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
US20050203053A1 (en) 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US6077558A (en) * 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
EP0951842B1 (en) * 1999-01-20 2002-12-04 N.V. Nutricia Infant formula
ES2250112T3 (es) 1999-03-08 2006-04-16 Medicure Inc. Analogos de piridoxal para el tratamiento de trastornos causados por carencia de vitamina b6.
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
AU784840B2 (en) 2000-03-28 2006-07-06 Medicure International Inc. Treatment of cerebrovascular disease
US6495599B2 (en) * 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6787761B2 (en) * 2000-11-27 2004-09-07 Surromed, Inc. Median filter for liquid chromatography-mass spectrometry data
US6511696B2 (en) 2000-12-13 2003-01-28 Novartis Nutrition Ag Infant formula with free amino acids and nucleotides
GB0104778D0 (en) * 2001-02-27 2001-04-18 Rhodia Cons Spec Ltd Production of aromatic phosphites
US6620427B2 (en) 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
CA2445512C (en) 2001-04-25 2010-10-12 Cobalz Limited A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method
US7169416B2 (en) 2001-05-23 2007-01-30 Nutricopia, Inc. Nutritional frozen dessert and methods of manufacture
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US20050019372A1 (en) 2001-07-10 2005-01-27 Barbara E Corkey Modified-fat nutritional products useful preventing or treating obesity
EP1279400A1 (en) 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
GB2381451A (en) 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US20040048926A1 (en) 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
WO2004002232A1 (en) * 2002-06-28 2004-01-08 Theuer Richard C Fat compositions for infant formula and methods therefor
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
EP1542670B2 (en) 2002-09-24 2023-07-05 Suntory Holdings Limited Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities in adults
ATE419759T1 (de) 2002-10-10 2009-01-15 Wyeth Corp Nukleotidhaltige fertig-babynahrung
EP1426053A1 (en) 2002-12-03 2004-06-09 Fresenius Kabi Deutschland GmbH Use of amphiphilic lipids for reducing tumor metastasis
US6753350B1 (en) * 2003-03-24 2004-06-22 Bristol-Myers Squibb Company Method to reduce the incidence of intraventricular hemorrhage in preterm infants
US7867541B2 (en) * 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
US6926167B2 (en) 2003-06-23 2005-08-09 Lazhar Mazlout Carton dispensing machine
GB0314624D0 (en) * 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
PL1638414T3 (pl) * 2003-06-23 2009-12-31 Nestec Sa Mleko modyfikowane niemowlęce lub następne
US8394370B2 (en) * 2003-06-23 2013-03-12 Nestec S.A. Nutritional formula for optimal gut barrier function
EP1643862A1 (en) * 2003-06-24 2006-04-12 University of Kansas Medical Center Infant formula
EP1665940A4 (en) 2003-09-02 2011-01-19 Bbk Bio Corp DIETETIC FOODSTUFF
GB0321996D0 (en) 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
IL158554A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
WO2005063050A1 (en) 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
EP1566439A1 (en) * 2004-02-20 2005-08-24 Nestec S.A. Preventing or treating obesity
US7090879B2 (en) 2004-03-18 2006-08-15 Abbott Laboratories Nutritional formula containing select carotenoid combinations
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1723951A1 (en) * 2005-04-21 2006-11-22 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
CA2574360A1 (en) * 2004-07-19 2006-01-26 N.V. Nutricia A preparation for use of aspartate for regulating glucose levels in blood
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1811865B1 (en) 2004-11-26 2008-07-16 N.V. Nutricia Infant nutrition with protease inhibitor
HU227588B1 (hu) * 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény
US20100022451A1 (en) 2004-12-27 2010-01-28 Nestec S.A. Use of infant formula with reduced protein content
PL2805625T5 (pl) * 2005-02-28 2023-03-13 N.V. Nutricia Kompozycja odżywcza z prebiotykami i probiotykami
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US7829126B2 (en) * 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
EP1803358A1 (en) * 2005-12-28 2007-07-04 Laboratorios Ordesa, S.L Infant immunological formula

Also Published As

Publication number Publication date
PL1800675T4 (pl) 2012-02-29
US8076282B2 (en) 2011-12-13
US9446014B2 (en) 2016-09-20
USRE45483E1 (en) 2015-04-21
ES2855154T3 (es) 2021-09-23
MY172306A (en) 2019-11-21
EP2342976A3 (en) 2015-12-09
BRPI0620245A2 (pt) 2011-11-08
EP1800675A1 (en) 2007-06-27
US8119142B2 (en) 2012-02-21
EP2342976A2 (en) 2011-07-13
CN101370395A (zh) 2009-02-18
EP2342975A2 (en) 2011-07-13
CN101360489A (zh) 2009-02-04
WO2007073178A2 (en) 2007-06-28
CN101384184B (zh) 2013-03-06
CN101389227A (zh) 2009-03-18
CN101384184A (zh) 2009-03-11
EP2356914B1 (en) 2020-12-09
US8546325B2 (en) 2013-10-01
WO2007073177A2 (en) 2007-06-28
US20090156487A1 (en) 2009-06-18
CN101389227B (zh) 2012-09-26
WO2007073176A2 (en) 2007-06-28
EP2342978A3 (en) 2014-10-22
EP1976396B1 (en) 2020-10-14
EP1976395A2 (en) 2008-10-08
EP1976504B1 (en) 2021-10-06
EP2342977A2 (en) 2011-07-13
EP2342979A2 (en) 2011-07-13
EP2356914A3 (en) 2014-01-01
ES2851153T3 (es) 2021-09-03
MY176679A (en) 2020-08-19
US9463176B2 (en) 2016-10-11
PL2359701T3 (pl) 2021-07-05
ES2366034T3 (es) 2011-10-14
EP2342977A3 (en) 2013-06-05
US8497238B2 (en) 2013-07-30
EP1976504A2 (en) 2008-10-08
PL1800675T3 (pl) 2011-10-31
US20080317868A1 (en) 2008-12-25
PL1976504T3 (pl) 2022-01-03
EP2359701B1 (en) 2021-01-06
WO2007073175A3 (en) 2008-06-26
AR058751A1 (es) 2008-02-20
WO2007073177A3 (en) 2008-07-17
EP2342978A2 (en) 2011-07-13
CN101360489B (zh) 2015-02-18
ATE509624T1 (de) 2011-06-15
EP1983976A2 (en) 2008-10-29
EP1800675B1 (en) 2011-05-18
PT1800675E (pt) 2011-08-30
EP2342979A3 (en) 2014-02-05
EP2342975A3 (en) 2014-10-22
AR058753A1 (es) 2008-02-20
CN101370396A (zh) 2009-02-18
CN107495379A (zh) 2017-12-22
ES2894338T3 (es) 2022-02-14
EP2356914A2 (en) 2011-08-17
WO2007073176A3 (en) 2008-09-12
US20130295146A1 (en) 2013-11-07
US20080292649A1 (en) 2008-11-27
EP1983976B1 (en) 2018-08-15
CN101370491A (zh) 2009-02-18
US20090022813A1 (en) 2009-01-22
WO2007073175A2 (en) 2007-06-28
EP2342974A3 (en) 2015-12-09
EP1976396A2 (en) 2008-10-08
BRPI0620416A2 (pt) 2011-11-08
EP2342974A2 (en) 2011-07-13
PL2356914T3 (pl) 2021-05-17
DK1800675T3 (da) 2011-09-05
EP2359701A1 (en) 2011-08-24
WO2007073178A3 (en) 2008-06-05
CN101400344A (zh) 2009-04-01
BRPI0620244A2 (pt) 2011-11-08
US20120064127A1 (en) 2012-03-15
US20080292724A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
AR058752A1 (es) Composiciones para bebes para prevenir la obesidad
AR063774A1 (es) Uso de composiciones nutricionales para prevenir trastornos
Whelan et al. Dietary (n-6) PUFA and intestinal tumorigenesis
ES2196983B1 (es) Polvo nutriente para una formula infantil con aminoacidos libres y nucleotidos.
AR044867A1 (es) Composicion nutritiva para infantes
Picchi et al. A high-fat diet as a model of fatty liver disease in rats
BRPI0514498A (pt) composição nutricional, e, uso da composição nutricional
ATE508642T1 (de) Hydroxytyrosol-verstärkte öle und deren verwendung
DK1876906T3 (da) Kosttilskud eller functional food, indeholdende oliekombination
MY143654A (en) Use of a nutritional formulation for promoting catch-up growth
RU2011104077A (ru) Питательная композиция со свободными аминокислотами и структурированными липидами
RU2011120780A (ru) Питательная композиция, способствующая здоровому развитию и росту
BRPI0804489A2 (pt) ácidos graxos de cadeia longa para redução do sabor desagradável de edulcorantes não nutritivos
AR073359A1 (es) Composiciones nutricionales con globulos lipidicos recubiertos
MY166945A (en) Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
MY162091A (en) Infant nutritional compositions for preventing obesity
CL2011003078A1 (es) Uso de una composicion nutricional para mantener, sostener y/o mejorar el desempeno cognitivo en un nino de 3 a 6 anos, que comprende al menos una fuente de proteina, una fuente de carbohidratos, una fuente de lipido, un microorganismo probiotico, y prebioticos, en donde la fuente de lipido comprende acido docosahexanoico (dha).
RU2014111760A (ru) Пищевые композиции с фитодобавкой
EA200970238A1 (ru) ПРИМЕНЕНИЕ МАСЕЛ С DPA(n-6) В ДЕТСКОМ ПИТАНИИ
ATE471665T1 (de) Nahrungsergänzungsmittel für hiv-patienten
BRPI0416403A (pt) composição de óleo enriquecida em diglicerìdeo com ácido linoléico conjugado
BR112013024189A2 (pt) métodos para aprimorar saúde óssea em crianças com o uso de ácidos graxos poli-insaturados de cadeia longa
AR035693A1 (es) Aceite que contiene uno o unos acidos grasos poliinsaturado(s) de larga cadena resultantes de biomasa, procedimiento de preparacion, alimento, composicion nutricional,cosmetica o farmaceutica que lo contiene.
López-Domínguez et al. The influence of dietary fat source on life span in calorie restricted mice
AR110060A1 (es) Composiciones nutricionales que proporcionan el manejo dietético de cólicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure